BRCA1 and ovarian carcinoma: In 2020, the American Society of Clinical Oncology (ASCO) recommended molecular tumor testing for BRCA1/2 mutations in all epithelial ovarian cancer patients who were germline negative and recommended testing for mismatch repair (MMR) deficiency in patients with clear cell, endometrioid, or mucinous cancers [3].